Results
Considering the primary endpoint, exercise tolerance at 12 weeks, omapatrilat and lisinopril are equivalent:
- 24 sec increase in the omapatrilat group
- 31 sec increase in the lisinopril group (p=0.45)
There was a significant effect on the secondary endpoint of death, admission or discontinuation of treatment due to worsening heart failure:
- hazard ratio 0.52 (p=0.035)
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.